Intelligence Report

Isomorphic Labs lands $5 billion Series C to push AI-designed drugs toward trials

The DeepMind spinout's round, co-led by Greenoaks and Sequoia Capital, follows a $2.1 billion Series B that closed in May.

INSIGHTEX Editorial Desk

2 min read

Isomorphic Labs lands $5 billion Series C to push AI-designed drugs toward trialsIntelligence Report

What happened

Isomorphic Labs, the AI drug-discovery company that Google's DeepMind spun out in 2021, has closed a $5 billion Series C round intended to move its drug candidates into clinical trials, TechCrunch reported. Greenoaks and Sequoia Capital co-led the financing, and Andreessen Horowitz came in as a new investor alongside other participants.

Every existing backer also took part, among them Alphabet's venture arms GV and Capital G, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. The company plans to put the money toward further development of its drug-design engine and toward expanding into additional types of medicine. It did not reveal the valuation attached to the round.

The engine draws on a range of simulation AI models that probe different areas of chemistry to guide drug design, and it builds on DeepMind's AlphaFold protein-folding model. The company said its program has produced positive preclinical findings in both oncology and immunology. It has signed agreements with Eli Lilly, Novartis and Johnson & Johnson.

Context

AlphaFold, the DeepMind system that predicts a protein's 3D structure from its genetic sequence, won Demis Hassabis and John Jumper the Nobel Prize in chemistry. Hassabis, Isomorphic's founder and CEO, later stepped down as head of DeepMind to focus on drug discovery and became its chairman. This is Isomorphic's first raise since that change. Bloomberg reported earlier this month that the company sought a $50 billion valuation.

Andreessen Horowitz profile

Google profile

SourceTechCrunch

The briefing

The week in tech, in one email.

The stories worth your time, every week. Unsubscribe anytime.